Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2007

Debiopharm Receives cGMP Certification for QC of Drug Products

  • Debiopharm achieved cGMP certification from Swissmedic for the chemical, physical, and biochemical quality control work conducted at its laboratory in Gland, Switzerland. Debiopharm now has the alternative to handle its analytical development, formulation, and quality control activities in-house when necessary, according to Kamel Besseghir, CEO.

    Debiopharm also has a cGMP development and production facility in Martigny, Switzerland, which has been inspected by the FDA and Swissmedic. The company reports that it can produce pilot batches of cGMP drug products for feasibility studies, clinical trial supplies, and commercial-scale manufacturing.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »